$0.34 EPS Expected for Qiagen NV (NYSE:QGEN) This Quarter

Wall Street analysts expect Qiagen NV (NYSE:QGEN) to announce earnings of $0.34 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Qiagen’s earnings. The lowest EPS estimate is $0.33 and the highest is $0.35. Qiagen reported earnings per share of $0.33 during the same quarter last year, which would suggest a positive year-over-year growth rate of 3%. The company is expected to issue its next earnings results on Tuesday, July 30th.

According to Zacks, analysts expect that Qiagen will report full-year earnings of $1.43 per share for the current financial year, with EPS estimates ranging from $1.41 to $1.44. For the next financial year, analysts expect that the company will post earnings of $1.60 per share, with EPS estimates ranging from $1.55 to $1.63. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Qiagen.

Qiagen (NYSE:QGEN) last posted its earnings results on Monday, May 6th. The company reported $0.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.01. The business had revenue of $348.70 million for the quarter, compared to analyst estimates of $351.68 million. Qiagen had a net margin of 12.45% and a return on equity of 12.22%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.26 EPS.

QGEN has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Qiagen from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research note on Friday, April 12th. Goldman Sachs Group reaffirmed a “buy” rating on shares of Qiagen in a research note on Tuesday, May 7th. UBS Group began coverage on shares of Qiagen in a research note on Friday, March 15th. They set a “neutral” rating and a $42.00 target price for the company. Finally, Wolfe Research began coverage on shares of Qiagen in a research report on Thursday, May 30th. They issued a “peer perform” rating for the company. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Qiagen has an average rating of “Buy” and a consensus target price of $41.71.

Several institutional investors have recently made changes to their positions in QGEN. Lindbrook Capital LLC bought a new position in shares of Qiagen in the fourth quarter worth about $25,000. O Shaughnessy Asset Management LLC bought a new position in shares of Qiagen in the 1st quarter worth $30,000. Captrust Financial Advisors lifted its holdings in shares of Qiagen by 165.3% in the 4th quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock worth $35,000 after purchasing an additional 628 shares in the last quarter. Cornerstone Advisors Inc. bought a new position in shares of Qiagen in the 1st quarter worth $44,000. Finally, Bremer Trust National Association bought a new position in Qiagen during the 4th quarter valued at $45,000. 63.22% of the stock is owned by institutional investors.

QGEN stock traded up $0.09 during trading on Monday, reaching $39.61. The stock had a trading volume of 26,684 shares, compared to its average volume of 1,291,078. The firm has a market capitalization of $8.91 billion, a P/E ratio of 29.60, a P/E/G ratio of 2.37 and a beta of 0.84. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.69 and a quick ratio of 1.52. Qiagen has a 1-year low of $32.33 and a 1-year high of $41.55.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Recommended Story: How does a 12b-1 fee affect fund performance?

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.